Back to Journals » OncoTargets and Therapy » Volume 6

Review

Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC

       
Total article views   HTML views PDF downloads Totals
21,840 Dovepress* 13,661+ 3,202 16,863
PubMed Central* 8,179 2,178 10,357
Totals 21,840 5,380 27,220
*Since 5 March 2013
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
2 0 0 0 1 1

View citations on PubMed Central and Google Scholar